JP2023519837A5 - - Google Patents
Info
- Publication number
- JP2023519837A5 JP2023519837A5 JP2022557696A JP2022557696A JP2023519837A5 JP 2023519837 A5 JP2023519837 A5 JP 2023519837A5 JP 2022557696 A JP2022557696 A JP 2022557696A JP 2022557696 A JP2022557696 A JP 2022557696A JP 2023519837 A5 JP2023519837 A5 JP 2023519837A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- single expression
- elements
- vlp
- vector encodes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063002237P | 2020-03-30 | 2020-03-30 | |
| US63/002,237 | 2020-03-30 | ||
| US202063070150P | 2020-08-25 | 2020-08-25 | |
| US63/070,150 | 2020-08-25 | ||
| PCT/IB2021/000190 WO2021198769A1 (en) | 2020-03-30 | 2021-03-30 | Vaccine compositions for the treatment of coronavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023519837A JP2023519837A (ja) | 2023-05-15 |
| JP2023519837A5 true JP2023519837A5 (https=) | 2024-04-01 |
Family
ID=77927072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557696A Pending JP2023519837A (ja) | 2020-03-30 | 2021-03-30 | コロナウイルスを処置するためのワクチン組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11253587B2 (https=) |
| EP (1) | EP4126038A4 (https=) |
| JP (1) | JP2023519837A (https=) |
| KR (1) | KR20230008707A (https=) |
| AU (1) | AU2021247583A1 (https=) |
| BR (1) | BR112022019672A2 (https=) |
| CA (1) | CA3142132C (https=) |
| IL (1) | IL296578A (https=) |
| MX (1) | MX2022012192A (https=) |
| WO (1) | WO2021198769A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12558415B2 (en) * | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2021234579A1 (en) * | 2020-05-19 | 2021-11-25 | National Research Council Of Canada | Use of resistin as a trimerization partner for expression of trimeric proteins |
| WO2022051859A1 (en) * | 2020-09-11 | 2022-03-17 | Manuel Caruso | Pseudotyped retroviral particles for inducing immunity against coronavirus infections |
| KR102744743B1 (ko) * | 2021-10-25 | 2024-12-19 | 경희대학교 산학협력단 | SARS-CoV-2의 스파이크 단백질 전부 또는 일부를 포함하는 바이러스 유사입자 및 이를 이용한 백신 |
| EP4719470A1 (en) * | 2023-06-02 | 2026-04-08 | Variation Biotechnologies Inc. | Compositions of mrna-encoded virus-like particles, compositions of mrna-lipid nanoparticles, and methods for use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5500161A (en) | 1993-09-21 | 1996-03-19 | Massachusetts Institute Of Technology And Virus Research Institute | Method for making hydrophobic polymeric microparticles |
| WO2005118813A2 (en) * | 2004-06-04 | 2005-12-15 | Institut Pasteur | Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| JP6046348B2 (ja) | 2008-11-18 | 2016-12-14 | タケダ ヴァクシーンズ， インコーポレイテッド | Ｒｓｖｆｖｌｐならびにその製造および使用の方法 |
| US8920812B2 (en) | 2009-11-03 | 2014-12-30 | Takeda Vaccines, Inc. | Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS |
| WO2011115583A1 (en) | 2010-03-19 | 2011-09-22 | National University Of Singapore | A novel platform for retrovirus-like particle (vlp)-display of vaccine antigens |
| WO2014128568A2 (en) * | 2013-02-25 | 2014-08-28 | Variation Biotechnologies, Inc. | Compositions and methods for treatment of hepatitis c |
| MX2019000725A (es) * | 2016-07-18 | 2019-07-04 | Variation Biotechnologies Inc | Composiciones de vacuna para tratamiento de virus zika. |
-
2021
- 2021-03-30 KR KR1020227037855A patent/KR20230008707A/ko active Pending
- 2021-03-30 JP JP2022557696A patent/JP2023519837A/ja active Pending
- 2021-03-30 WO PCT/IB2021/000190 patent/WO2021198769A1/en not_active Ceased
- 2021-03-30 CA CA3142132A patent/CA3142132C/en active Active
- 2021-03-30 MX MX2022012192A patent/MX2022012192A/es unknown
- 2021-03-30 AU AU2021247583A patent/AU2021247583A1/en not_active Abandoned
- 2021-03-30 US US17/218,148 patent/US11253587B2/en not_active Expired - Fee Related
- 2021-03-30 EP EP21782275.8A patent/EP4126038A4/en not_active Withdrawn
- 2021-03-30 IL IL296578A patent/IL296578A/en unknown
- 2021-03-30 BR BR112022019672A patent/BR112022019672A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023519837A5 (https=) | ||
| Franchini et al. | Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses | |
| EP2359851A3 (en) | MVA expressing modified hiv envelope, gag, and pol genes | |
| Eschli et al. | Identification of an N-terminal trimeric coiled-coil core within arenavirus glycoprotein 2 permits assignment to class I viral fusion proteins | |
| Chakrabarti et al. | Expression of the HTLV-III envelope gene by a recombinant vaccinia virus | |
| Fäcke et al. | A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum | |
| LaBranche et al. | A single amino acid change in the cytoplasmic domain of the simian immunodeficiency virus transmembrane molecule increases envelope glycoprotein expression on infected cells | |
| JP2003527064A5 (https=) | ||
| DK1372710T3 (da) | MVA der udtrykker modificeret HIV-kappe-, Gag- og Pol-gener | |
| AR029759A1 (es) | Variante de glucoamilasa original, una construccion de adn, un vector de expresion recombinante, una celula, un proceso para convertir almidon, uso de una variante de glucoamilasa para un proceso de fermentacion y metodo para mejorar la estabilidad termica. | |
| Ritter Jr et al. | Human immunodeficiency virus type 2 glycoprotein enhancement of particle budding: role of the cytoplasmic domain | |
| JP2012509340A5 (https=) | ||
| JP2019214579A5 (https=) | ||
| JP2004533208A5 (https=) | ||
| NO20075752L (no) | Kimeriske proteiner, deres fremstilling og farmasoytiske sammensetninger som inneholder dem | |
| Cifuentes-Munoz et al. | Aromatic and polar residues spanning the candidate fusion peptide of the Andes virus Gc protein are essential for membrane fusion and infection | |
| WO2006026667A3 (en) | Recombinant mva viruses expressing glade a/g, clade b, and clade c modified hiv, gag and pol genes | |
| Manrique et al. | Mutational analysis of the feline immunodeficiency virus matrix protein | |
| Hourioux et al. | Identification of the Glycoprotein 41™ Cytoplasmic Tail Domains of Human Immunodeficiency Virus Type 1 That Interact with Pr55Gag Particles | |
| WO2005002501A3 (en) | Novel druggable regions in the dengue virus envelope glycoprotein and methods of using the same | |
| RU2006123079A (ru) | Вирусные частицы, содержащие вектор, происходящий из альфавируса, и способ получения указанной вирусной частицы | |
| Manrique et al. | Functional relationship between the matrix proteins of feline and simian immunodeficiency viruses | |
| ATE509942T1 (de) | Nichtproteolysierbare oligopeptide, die das glycoprotein gp41 von hiv inhibieren | |
| Tagliamonte et al. | Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies | |
| Maillard et al. | Homology-based identification of capsid determinants that protect HIV1 from human TRIM5α restriction |